What are the Chinese and English names of Revumenib?

Revumenib is a new type of oral small molecule targeted drug, mainly used to treat acute myeloid leukemia (AML) and other hematological malignancies. The drug, developed by Kura Oncology, is a NEDD8- activating enzyme (NAE) inhibitor. It can inhibit the proliferation and survival of cancer cells by blocking the degradation pathways of key proteins in cells. As an innovative treatment option, Revimenib has shown great potential in the field of hematological cancer treatment.

The English name of Revumenib is“Revumenib”, which is its internationally accepted trade name. In the Chinese market, the drug has not yet been officially approved for marketing, so it does not yet have a widely recognized standard Chinese name. However, according to drug naming conventions and transliteration habits, it is usually called "Revimenib". This name is gradually adopted in medical literature and clinical trial reports to facilitate the identification and communication between doctors and patients.

As a targeted drug, Revemenib mainly targets subtypes of AML patients with specific gene fusion abnormalities, especially leukemias involving nuclear receptor transcription factors (such as KMT2A fusion proteins). By interfering with the function of these abnormal proteins, Revimenib can effectively inhibit the growth of tumor cells and induce their apoptosis, thereby improving the patient's remission rate and survival rate. Currently, Revimenib is undergoing multiple international clinical trials to evaluate its efficacy and safety, and it is expected to obtain marketing approval from more countries as soon as possible.

In general, Revumenib (Revumenib) is an innovative drug that represents the direction of precision treatment of hematological tumors. Although it is not yet on the market in China, its potential clinical value has received widespread attention. With the accumulation of more clinical data and the advancement of regulatory approvals, Revimenib is expected to bring new treatment options and hope to patients with acute myeloid leukemia and other hematological malignancies in the future.

Reference materials:https://www.drugs.com/